

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except share and per share information)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2020	2019	2020	2019
Grant and collaboration revenue	\$ 415	\$ 333	\$ 1,572	\$ 907
Operating expenses:				
Research and development	417	468	1,687	1,475
General and administrative	435	291	1,365	1,214
	<u>852</u>	<u>759</u>	<u>3,052</u>	<u>2,689</u>
Loss from operations	(437)	(426)	(1,480)	(1,781)
Other income (expense), net	(134)	2	(142)	1
Net loss	<u>\$ (571)</u>	<u>\$ (424)</u>	<u>\$ (1,622)</u>	<u>\$ (1,780)</u>
Loss per common share	<u>\$ (0.73)</u>	<u>\$(1,282.28)</u>	<u>\$ (2.85)</u>	<u>\$(14,016.03)</u>

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except share information)

	Sep. 30, 2020	Dec. 31, 2019
Assets:		
Cash and cash equivalents	\$ 11,581	\$ 283
Other current assets	154	164
Total current assets	<u>11,735</u>	<u>447</u>
Property and other assets, net	21	22
Total assets	<u>\$ 11,756</u>	<u>\$ 469</u>
Liabilities and stockholders' equity (deficiency)		
Total liabilities	\$ 942	\$ 2,043
Stockholders' equity (deficiency)	10,814	(1,574)
Total liabilities and stockholders' equity (deficiency)	<u>\$ 11,756</u>	<u>\$ 469</u>
Common Shares Outstanding	3,559,473	14,992